RxDoctor Payments Data

Sarah Smith, MD

Ophthalmology · Youngstown, OHNPI 1053639161

Payments from drug & device makers

$2,203in general payments, 2019–2025

Across 86 payments — averaging $25.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$310
  • Apellis Pharmaceuticals, Inc.$268
  • Regeneron Healthcare Solutions, Inc.$260
  • NEW World Medical,inc.$199
  • Sun Pharmaceutical Industries Inc.$179
  • Aerie Pharmaceuticals, Inc.$132
  • plus $856 from 19 others

What the payments were for

  • Food & beverage$2,203100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,203 in reported general payments places this provider in the 60th percentile of 640 ophthalmology providers in Ohio.

See all ophthalmology providers in Ohio

Medicare billing

Part B allowed, 2024
$1,405,851
Medicare patients
754
Services billed
10,674

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine15$20,860
XiidraLifitegrast15$16,837
LumiganBimatoprost16$11,898
RocklatanNetarsudil Mesylat/Latanoprost20$9,553
VyzultaLatanoprostene Bunod29$9,204
Prednisolone Acetate206$6,507
CombiganBrimonidine Tartrate/Timolol15$4,010
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol46$3,942
Difluprednate35$3,469
Ketorolac Tromethamine174$2,964
Latanoprost217$2,323
Ofloxacin87$910
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat37$544
Dorzolamide Hcl18$527
Brimonidine Tartrate72$409

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$43$36,76946 claims
Aerie Pharmaceuticals, Inc.Rocklatan$132$9,55320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 640 ophthalmology providers in Ohio.

Other ophthalmology in Youngstown

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →